Cord Blood Glutathione Depletion in Preterm Infants: Correlation with Maternal Cysteine Depletion

Alice Küster1,2, Illa Tea3, Véronique Ferchaud-Roucher2, Sabrina Le Borgne3, Claire Plouzennec3, Norbert Winer1,4, Jean-Christophe Rozé1,2, Richard J. Robins3, Dominique Darmaun1,6*

1 UMR Physiologie des Adaptations Nutritionnelles, INRA, Université de Nantes, France, 2Division of Neonatology, CHU de Nantes & INSERM, Centre d’Investigation Clinique, Nantes, France, 3CNRS, UMR 6230, Université de Nantes, France, 4Division of Obstetrics, CHU de Nantes, & INSERM, Centre d’Investigation Clinique, Nantes, France, 5Mass Spectrometry Core Facility, CRNH, Nantes, France, 6Research Laboratory, Nemours Children’s Clinic, Jacksonville, Florida, United States of America

Abstract

Background: Depletion of blood glutathione (GSH), a key antioxidant, is known to occur in preterm infants.

Objective: Our aim was to determine: 1) whether GSH depletion is present at the time of birth; and 2) whether it is associated with insufficient availability of cysteine (cys), the limiting GSH precursor, or a decreased capacity to synthesize GSH.

Methodology: Sixteen mothers delivering very low birth weight infants (VLBW), and 16 mothers delivering healthy, full term neonates were enrolled. Immediately after birth, erythrocytes from umbilical vein, umbilical artery, and maternal blood were obtained to assess GSH [GSH] and cysteine [cys] concentrations, and the GSH synthesis rate was determined from the incorporation of labeled cysteine into GSH in isolated erythrocytes ex vivo, measured using gas chromatography mass spectrometry.

Principal Findings: Compared with mothers delivering at full term, mothers delivering prematurely had markedly lower erythrocyte [GSH] and [cys] and these were significantly depressed in VLBW infants, compared with term neonates. A strong correlation was found between maternal and fetal GSH and cysteine levels. The capacity to synthesize GSH was as high in VLBW as in term infants.

Conclusion: The current data demonstrate that: 1) GSH depletion is present at the time of birth in VLBW infants; 2) As VLBW neonates possess a fully active capacity to synthesize glutathione, the depletion may arise from inadequate cysteine availability, potentially due to maternal depletion. Further studies would be needed to determine whether maternal-fetal cysteine transfer is decreased in preterm infants, and, if so, whether cysteine supplementation of mothers at risk of delivering prematurely would strengthen antioxidant defense in preterm neonates.

Introduction

Premature birth abruptly propels the fetus from the protected, relatively hypoxic intrauterine milieu into an environment with a high oxygen pressure, and further exposes the preterm infant to free radical injury from mechanical ventilation strategies, including the use of high inspired oxygen fractions or inhaled nitric oxide, and from reactive oxidative species (ROS) produced by sepsis and/or inflammatory response. Physiological perturbation is further enhanced because preterm have diminished antioxidant defenses and are highly vulnerable to oxidative stress [1]. Evidence for peroxidation of lipids and proteins is found in several tissues in premature infants [2,3], and oxidative stress is involved in the pathophysiology of several diseases associated with prematurity, such as retinopathy, bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis [4].

The tripeptide glutathione (GSH), or L-γ-glutamyl-L-cysteinyl-glycine, is the most abundant intracellular antioxidant and is actively produced in nearly all mammalian cells, where its concentration reaches the millimolar range. The maintenance of intracellular GSH stores depends on the capacity of the cell’s enzymatic equipment for GSH synthesis, the availability of precursor substrates, and the cell’s ability to recycle oxidized glutathione (GSSG) into its active reduced form, GSH. Depletion of blood GSH has been demonstrated in premature infants after a few days of life [3,6], and blood GSH correlates with gestational age [5]. Cysteine availability has been considered limiting for the synthesis of GSH in other pathological situations, such as malnutrition or human immuno-deficiency virus infection, since providing cysteine has been shown to stimulate GSH synthesis and restore GSH stores in such situations [7,8].
Early in life, cysteine may be an essential amino acid, as the transsulfuration pathway producing cysteine from methionine and serine via homocysteine, is not fully active, since activity of cystathionine-γ-hex is barely detectable in human fetal tissues [9–13]. Although both enterally [16] and parenterally [17] fed premature infants have been shown to be able to produce cysteine, the capacity for intrahepatic de novo cysteine synthesis appears to be directly proportional to the maturity of the neonate [10]. Nevertheless, providing cysteine even in high doses to preterm infants after birth seems neither to increase [GSH] nor to enhance GSH synthesis rate [18].

To obtain further insight into the mechanisms involved in the GSH deficiency observed in premature infants, we have compared the [GSH] and [cys] in umbilical cord blood from very low birth weight infants (VLBW) (gestational age (GA) <32 weeks and/or birth weight <1500 g) with that of healthy full term newborns. Fractional synthesis rates of GSH, (FSRGSH) were also determined in vitro following the incorporation of L-[3H2]cysteine into erythrocyte glutathione. All measurements were performed in blood erythrocytes obtained immediately after birth from umbilical arteries and veins and in maternal venous blood. Erythrocytes were chosen for measurements instead of plasma because of their highly active GSH synthesis contributing in large amounts besides liver to the GSH pool of the preterm. We hypothesized that the GSH depletion observed in preterm infants would already be present at the time of birth, and may be due to insufficient cysteine availability from maternofetal cysteine transfer rather than to an insufficient capacity for GSH synthesis.

**Methods**

**Design**

The study was registered (ClinicalTrials.gov Identifier: NCT00607061), and performed in the Department of Obstetrics of the Hôpital Mère-Enfant at the University of Nantes after approval by the local medical ethical committee (Comité de Protection des Personnes dans la recherche biomédicale (CPP) des Pays de la Loire). The study was investigator-initiated and funded by the Hospital of Nantes. Written, informed consent was obtained from every mother, a few hours before delivery.

Umbilical cord blood samples were collected in the delivery room simultaneously with sampling for blood gas analysis by the midwife. As umbilical cord is routinely discarded after sampling, the samples obtained for the current study did not involve any additional blood loss for the neonates.

Umbilical cord blood was obtained from VLBW infants (n = 16), and in a control group of healthy, full-term neonates (n = 16) in order to determine [GSH]. Furthermore, FSRGSH were determined in vitro in erythrocytes obtained from half of the babies in the VLBW group (n = 8) and compared with half of the control group of neonates born at term (n = 8). Assessment of FSRGSH in umbilical cord blood erythrocytes necessitated immediate handling of samples after birth with a narrow cooperation of the neonatal care team and the GCMS laboratory team. To obtain insight into the role of the materno-fetal unit (including placenta) in cysteine and GSH exchange, all analyses were performed in blood from three sites: the umbilical vein providing information about blood directed from the placenta to the fetus; in samples collected from one of the two umbilical arteries representing blood of the fetus redistributed to placenta; and in order to relate these results to the status of the mothers, we also collected maternal venous blood samples at delivery.

**Subjects**

The subjects were 16 inborn VLBW infants born before 32 weeks of GA and/or with a birth weight <1500 g, and a control group of 16 inborn neonates born at term after an uneventful pregnancy and delivery. Umbilical arterial and venous cord blood was obtained immediately after birth. Maternal venous blood was collected at delivery for every neonate included in order to obtain maternal infant pairs for comparison between the preterm delivery and the control group. In 8 VLBW infants chosen at random from the 16 subjects, [GSH] and [cys] were determined and compared with 8 healthy full term neonates also chosen at random. In the remaining groups of 8 VLBW infants and 8 full-term infants, the fractional synthesis rate of GSH, (FSRGSH), and [GSH] were determined in order to compare them also to 8 full-term neonates chosen at random.

Inclusion criterion for VLBW infants was a GA <32 weeks and/or a birth weight <1500 g. Inclusion criteria for the control group were: a GA >37 weeks, and uneventful pregnancy and delivery.

Exclusion criteria for the VLBW group were: perinatal asphyxia defined as pH <7.2 in umbilical cord blood and/or difference between arterial and venous pH <0.2, or major fetal pathology (abnormal karyotype, malformation, foetal pathology revealed during pregnancy).

Exclusion criteria for control group were: perinatal asphyxia, major fetal pathology, bacterial or viral infection, or maternal arterial blood pressure >90 mm Hg during pregnancy.

**Measurement of glutathione and cysteine concentrations**

Using antioxidant dithiothreitol (DTT) that reduces all thiol dimers, [GSH] was measured as total GSH (reduced GSH plus oxidized GSH, the disulfide GSSG) and [cys] as total cysteine (reduced cysteine plus oxidized cysteine). Hence, values include various GSH and cysteine-containing and protein-linked disulfides in addition to free monomers. Erythrocytes provided from maternal, venous, and arterial umbilical cord blood were chosen for measurements, as they are more readily available than tissue samples and have a highly active GSH synthesis with an active export towards plasma, contributing besides the liver to the extracellular GSH pool. Umbilical cord blood is moreover easy to collect and non invasive for the neonate. Determinations were performed by gas chromatography-mass spectrometry using homoglutathione as an internal standard, as previously described [19].

**Measurement of in vitro fractional rates of glutathione synthesis (FSRGSH)**

Previous work established optimal conditions to synthesize GSH in vitro and thereby to determine FSRGSH [19–21]. Immediately after sampling in delivery room, freshly sampled blood erythrocytes were washed twice by centrifugation of the blood samples and replacement of the supernatant volume by volume by 0.9% NaCl in order to remove enzymes contained on the surface and potentially influencing glutathione metabolism. Erythrocytes contained in the remnant phase after the last centrifugation were disrupted by adding a volume of ice cold distilled water equal to the volume of plasma discarded. A 2-mL aliquot of lysed erythrocytes was then incubated at 37°C with 2 mL of a solution (adjusted to pH 7.5 with NaOH (10 mol/L) containing: L-[3H2]cysteine (98% enriched, Cambridge Isotopes, Andover, Mass) at a concentration of 500 μmol/L, glutamate (600 mmol/L), glycine (400 mmol/L), ATP (400 mmol/L), di-thiothreitol (400 mmol/L), glucose (400 mmol/L), MgCl2 (3 mol/L), thiothreitol (400 mmol/L), and Trizma® hydrochloride (400 mmol/L). Incubation of red blood cell lysates with these adequate amounts of substrates allowed determination of maximal FSRGSH. 400-μL aliquots were removed at 0, 10, 20, 30, 60 and 90 min after the start of incubation. The reaction was stopped immediately by the addition
of 375 µL of 50% (w/v) sulfoalicylic acid and 800 µL of 0.2 mol/L sodium phosphate buffer (pH 7.5). After centrifugation (3000×g for 15 min at 4°C), the supernatant was removed, filtered and each sample derivatized and analyzed by GCMS.

Calculations

Glutathione fractional synthesis rate (FSR_{GSH}, %/d) was determined from the incorporation of $^2$H$_2$-cysteine into red blood cell glutathione: FSR_{GSH} = 100 × $\Delta$[GSH]/$\Delta$t/Erb_{cys}, where Erb_{cys} is the $^2$H$_2$ enrichment in erythrocyte-free cysteine at plateau, $\Delta$[GSH]/$\Delta$t is the slope (MPE/h) of the regression line describing the rise in red blood cell $^2$H$_2$-glutathione enrichment (MPE) as a function of time (h) over the last 3 hours of incubation, and 24 and 100 convert FSR to percent per day. FSR_{GSH} represents the fraction of glutathione pool synthesized per unit of time.

Absolute synthesis rate (ASR_{GSH}, μmol/L per day) was calculated as:

$$\text{ASR}_{\text{GSH}} = \frac{\text{FSR}_{\text{GSH}}}{100} \times [\text{GSH}]$$

In earlier reports [19–21] and preliminary experiments (data not shown) we confirmed the determination of FSR to be reproducible, when it was measured in replicate samples from healthy adult volunteers, with a coefficient of variation of <5% between replicate measurements.

Statistics

Statistical analysis was performed using SPSS® version 14.0 (SPSS, Chicago, IL). Results are reported as median and interquartiles, and percentages were presented as percent [95% confidence interval]. Mann-Whitney U and Chi$^2$ tests were used to compare quantitative and proportion values, respectively. Spearman’s correlation test and regression analyses were used to evaluate the relationship between maternal and venous umbilical cord blood [cys] or [GSH]. Statistically significant differences were defined as when $p<0.05$.

**Results**

A total of 16 VLBW infants and 16 full term neonates were enrolled (Table 1). Half of the subjects ($n=8$) in each group were randomly chosen and included for determination of [GSH] and [cys] in arterial and venous umbilical cord blood. In the second half of each group ($n=8$) both FSR_{GSH} and [GSH] were determined. Both subgroups of VLBW infants were similar regarding gestational age and birthweight. All analyses were performed simultaneously in the infants’ mothers.

**Maternal and fetal erythrocyte GSH concentrations**

Maternal blood [GSH] was significantly lower in mothers giving birth before term than in those who delivered at full term (median: 337 μmol/L, [interquartile, 310–479 μmol/L] vs. median: 656 μmol/L, [interquartile, 494–838 μmol/L]; $p=0.0003$) (Figure 1A). Neither growth retardation nor preeclampsia (data not shown) was associated with lower maternal GSH levels than prematurity itself. Similarly, [GSH] in umbilical venous cord blood was significantly lower in VLBW compared with full term infants (median: 509 μmol/L, [interquartile, 461–623 μmol/L] vs. median: 868 μmol/L, [interquartile, 711–1013 μmol/L]; $p=0.001$) (Figure 1B). This was also the case for umbilical arterial blood [GSH] (434 μmol/L, [interquartile, 363–540 μmol/L] vs. 668 μmol/L, [interquartile, 450–733 μmol/L]; VLBW vs. full term; $p=0.02$), (Figure 1C). Arterial umbilical cord blood [GSH] were lower than venous umbilical cord blood [GSH] and this arterio-venous gradient was larger in full-term than in premature infants ($p=0.02$).

**Table 1.** Selected clinical characteristics of enrolled infants and their mothers.

|                          | Preterm infants | Full-term infants | p     |
|--------------------------|-----------------|-------------------|-------|
| Sex                      |                 |                   |       |
| Male, n                  | 8 (50%)         | 7 (40%)           |       |
| Female, n                | 8 (50%)         | 9 (60%)           |       |
| Birth weight, g          | 1160 [982–1317] | 3490 [3305–3669]  | <0.001|
| Gestational age, wk      | 29 [27–30]      | 40 [39–41]        | <0.001|
| Birth weight, z score    | -0.4 [-1.1–0.2] | -0.1 [-0.5–0.2]   | 0.29  |
| Umbilical cord blood pH   | 7.3 [7.2–7.3]   | 7.3 [7.2–7.4]     | 0.14  |
| Mode of delivery         |                 |                   | <0.001†|
| Vaginal, n               | 6 (40%)         | 16 (100%)         |       |
| Cesarean section, n      | 10 (60%)        | 0 (0%)            | <0.001|
| Antenatal steroids       | 15 (94%)        | 0 (0%)            | <0.001|
| Preeclampsia, n          | 6 (40%)         | 0 (0%)            | 0.02††|
| Chorioamniotitis, n      | 8 (50%)         | 0 (0%)            |       |
| Premature rupture of membranes (>12 hours antepartum), n | 6 (40%) | 0 (0%) |
| Apgar score at 5 min     | 10 [8–10]       | 10 [10–10]        | 0.12  |
| Infant haemoglobin g/dL  | 14.5 [13.6–16.3]| 16.3 [15.0–17.0]  | 0.05  |
| Maternal age, y          | 27 [24–34]      | 30 [27–35]        | 0.34  |
| Maternal haemoglobin g/dL| 11.6 [11.0–12.2]| 11.6 [11.0–12.2]  | 0.17  |

Data are reported as n (%) or median [interquartile]. † intra-group comparison of vaginal and cesarian delivery modes. †† intra-group comparison of preeclampsia (Mann-Whitney U or Chi$^2$ tests). doi:10.1371/journal.pone.0027626.t001
A strong correlation was observed between maternal and venous umbilical cord blood [GSH] ($r^2 = 0.65; p = 0.001$) (Figure 2A).

Maternal and fetal erythrocyte cysteine concentrations

Maternal blood [cys] was significantly lower in mothers who delivered preterm, compared with full term (median: 31.3 μmol/L, [interquartile, 26.3–33.2 μmol/L] vs. median: 62.0 μmol/L, [interquartile, 53.2–99.7 μmol/L]; $p = 0.001$) (Figure 3A). Similarly, venous umbilical [cys] was significantly decreased in VLBW compared with full-term neonates (median: 24.4 μmol/L, [interquartile, 23.4–27.8 μmol/L] vs. median: 53.5 μmol/L, [interquartile, 41.7–91.6 μmol/L]; $p = 0.001$) (Figure 3B). Accordingly, a strong correlation was observed between maternal and venous umbilical cord blood [cys] ($r^2 = 0.62; P = 0.001$), (Figure 2B).

Cysteine depletion was also found in umbilical arterial blood in VLBW infants (median: 28.6 μmol/L, [interquartile, 23.7–
Glutathione fractional synthesis rates

As shown in Table 2, the fractional synthesis rates of GSH (FSR₉GSH) determined in vitro in erythrocytes from VLBW infants did not differ from those measured in full term infants, regardless of the sampling site. When determined in arterial umbilical cord blood, there was even a (non significant) trend toward higher FSR₉GSH in VLBW infants than in full term infants. Absolute synthesis rates (ASR₉GSH) did not differ. Similarly, the term of delivery did not affect FSR₉GSH in maternal blood (Table 2).

Discussion

The findings of the current study demonstrate that blood glutathione depletion is already present at the time of birth in premature infants, compared with term infants. They further suggest that GSH depletion is not due to a defect in fetal GSH synthesis, as GSH synthetic rates measured in isolated erythrocytes were indistinguishable in preterm and term infants. Critically, evidence for a dramatic reduction in cysteine delivery to the preterm fetus is provided, with a 40% reduction in umbilical cord vein [cys] in preterm infants compared with term infants, and a 43% reduction in maternal blood from mothers delivering preterm babies. Taken collectively, the data suggest that the depletion in GSH associated with preterm birth may result from the combination of 1) increased fetal GSH utilization and 2) insufficient maternofoetal cysteine delivery.

The first interesting finding in the current study was a significant reduction in maternal [GSH] in the case of preterm delivery. The effect of pregnancy on GSH status is debated, and published data concerning maternal thiol concentrations are scarce. Even though pregnancy generates increased oxidative burden, in normal pregnancy antioxidant capacity increases with term [22]. The plasma concentrations of cysteine, GSH and homocysteine are lower in healthy, pregnant women at delivery than in nonpregnant women, and plasma cysteine are lower in the 3rd than 2nd trimester during uncomplicated pregnancy [26]. In preeclampsia, maternal cysteine and homocysteine levels were comparable to those in nonpregnant women, but GSH levels were lower, suggesting either accelerated GSH utilization or insufficient GSH synthesis [24,25]. In our population, preterm delivery occurred in a context of chorioamnionitis, premature rupture of membranes, or preeclampsia. All are associated with inflammation, which is known to affect redox balance [26]. In case of infection, bacterial products stimulate the release of inflammatory cytokines by decidual and fetal membranes, leading to preterm labor and generation of free radicals and ROS in fetal and maternal circulation [27]. Accordingly, premature rupture of membranes involves damage of collagen in the chorioamnion by tissue-damaging ROS molecules [27]. Finally, elevated levels of oxidized thiols have been reported in pregnancy complicated by preeclampsia [28]. A lower antioxidant capacity has been implicated in syncytiotrophoblast apoptosis and increased shedding into the maternal circulation with endothelial dysfunction that is considered a causative factor in the maternal hyperimmune response characterizing preeclampsia [29,30]. In the current study, preeclampsia was not associated with a further decline in maternal [GSH], compared with other causes of preterm birth, suggesting depletion of GSH is present regardless of the cause of preterm delivery and due to increased oxidative stress. The majority of mothers delivering preterm underwent a Caesarean section, versus none among the mothers delivering at full term (Table 1). Although preoperative fasting or stress due to the surgical procedure might impact oxidative stress, we could not find an influence of C-section on GSH (or cysteine) levels in this subgroup. Among the mothers who delivered preterm, all but one received antenatal steroids (Table 1), and antenatal steroids were found to attenuate oxidative stress (assessed by GSH/GSSG ratio) and oxidative damage to proteins and DNA [31]. The GCMS assay employed in our study implies the reduction of GSSG to GSH and therefore cannot distinguish between the reduced and the oxidized forms of GSH and measures only total GSH. For this reason, we cannot evaluate the capacity of the mother to regenerate GSH from GSSG. Yet the lower total glutathione, combined with unaltered GSH FSR (Table 2), suggests increased rates of GSH utilization in our population of mothers delivering preterm. Finally, as we only measured glutathione FSR in erythrocytes, we cannot draw any conclusion on the synthetic rate of GSH in maternal liver. Liver indeed is the main source of plasma GSH, and hepatic GSH synthesis might be assessed through a determination of GSH synthetic rate in plasma; the assay we used is, however, not sensitive enough to measure GSH synthesis in plasma, which has a
much lower GSH content (in the micro-, vs. the milli-molar range in erythrocytes). Erythrocyte GSH nevertheless accounts for the bulk of whole blood GSH, and may play a role in antioxidant defence even in extracellular medium [32].

In the VLBW infant group, we observed a significantly lower [GSH] determined in venous umbilical cord blood, which likely represents the sum of the GSH distributed from the placenta into fetal circulation and GSH produced by fetal erythrocytes. Even though earlier studies by Frosali et al [33] and Jean-Baptiste et al [34], found similar umbilical cord blood [GSH] between preterm and term infants, the population enrolled in the current study may not be strictly comparable, as the average birth weight was 1160g in our study, compared with 1734 and 1827 g in the studies by Frosali et al and Jean-Baptiste et al, respectively. We speculate that the slightly lower gestational age of the preterm infants enrolled in the current study may account for the difference with these earlier studies [33,34]. In studies performed several days after birth GSH depletion was observed in preterm infants before, with the lowest GSH content observed in the less mature infants: lower [GSH] in premature than in term newborns has been found in peripheral venous blood following birth with a more pronounced decrease of lymphocyte [GSH] on day 2 from birth on [5], and in erythrocytes of preterm with respiratory distress syndrome [6]. In cells from tracheal aspirates derived from oxygen-dependant newborn infants, intracellular total [GSH] has been found lower in male and in less mature infants [35]. Another study confirmed that GSH content in tracheal aspirates from preterm with IRDS is decreased [36]. Our study is first to demonstrate that GSH depletion is present in preterm infants as early as at the time of birth as we measured [GSH] in umbilical cord blood in the delivery room. We speculate that in the very preterm infants enrolled in the current study, either (a) GSH was depleted prior to birth due to the underlying cause of prematurity, or (b) the process of birth per se contributed to a precipitous drop in GSH during birth, resulting in low cord blood GSH at the time of sampling.

Figure 3. Cysteine concentration [cys] in erythrocytes from maternal blood (A), venous umbilical cord blood (B) and arterial umbilical cord blood (C) of preterm and full-term subjects. The boxplot shows the median (central horizontal line) and includes the 25th (lower box border) to 75th percentile (upper box border) of cysteine concentration (μmol/L). Preterm (n = 8) were compared with full-term (n = 8) subjects. Significant differences were observed between the groups (p<0.05) as assessed with the Mann-Whitney U test.

doi:10.1371/journal.pone.0027626.g003
Antioxidant reserve may be of crucial relevance at the moment of transition from fetal to neonatal life when the newborn is exposed to an oxidative environment, and GSH depletion may affect outcome, since oxidative-stress participates in the pathophysiology of necrotizing enterocolitis, retinopathy, periventricular leukomalacia and chronic lung disease [5,33,34]. Low plasma GSH levels during the first hours of life have indeed been found in infants with respiratory distress syndrome (RDS) [37] and in infants who later developed BPD [38].

As for cysteine, we observed cysteine depletion in VLBW infants and their mothers. The low cysteine levels observed in mothers of preterm infants are intriguing. From a theoretical standpoint, several factors could contribute to low maternal cysteine concentration, including: (a) insufficient dietary methionine intake; (b) poor conversion of methionine to cysteine; or (c) excess utilization of cysteine via cysteine utilization for glutathione synthesis or incorporation into body protein. The mothers of preterm infants had been hospitalized for an average of 10.2 days (versus 0.2 days for the group delivering at term) prior to delivery. preterm infants had been hospitalized for an average of 10.2 days (versus 0.2 days for the group delivering at term) prior to delivery. The two substrates indeed are tightly linked. First, depletion of cysteine, we observed cysteine depletion in VLBW infants and their mothers. The low cysteine levels observed in mothers of preterm infants are intriguing. From a theoretical standpoint, several factors could contribute to low maternal cysteine concentration, including: (a) insufficient dietary methionine intake; (b) poor conversion of methionine to cysteine; or (c) excess utilization of cysteine via cysteine utilization for glutathione synthesis or incorporation into body protein. The mothers of preterm infants had been hospitalized for an average of 10.2 days (versus 0.2 days for the group delivering at term) prior to delivery. So they ingested hospital food rather than home cooked food. The diet plan offered to the mothers was a regular hospital diet, and thus, mothers who ingested hospital food rather than home cooked food. The mothers of preterm infants had been hospitalized for an average of 10.2 days (versus 0.2 days for the group delivering at term) prior to delivery. The group delivering at term (n = 8) received the hospital diet, whereas the preterm group (n = 8) delivered prematurely did so because of conditions known to be associated with inflammation, and inflammation invariably is associated with increased oxidative stress, which, in turn enhances glutathione synthesis. Maternal cysteine depletion therefore likely results from the underlying disease that led to preterm delivery.

cysteine levels must be sufficiently high to meet the requirements both for protein synthesis and the production of GSH, but, conversely, must be kept below the threshold of cytotoxicity. GSH synthesis decreases with sulfur amino acid intakes that are marginal but adequate for protein synthesis, suggesting protein synthesis has a higher priority for cysteine than does GSH synthesis [41,42].

Our results suggest that umbilical venous cord blood [cys] may directly depend on maternal levels. Energy-dependent transfer of amino acids is the preferred route for essential amino acids, with little or no metabolism within the placenta [43], whereas non-essential amino acids may be processed, interconverted or consumed within the placenta. Cysteine entry to the fetal circulation is mediated by system x_c, a transport protein which transports cysteine in exchange for glutamate. Therefore, as cysteine is the rate-limiting precursor for GSH synthesis, the intracellular level of GSH is regulated by system x_c activity [43-45].

Cysteine may be a conditionally essential amino acid for preterm infants since cystathionase, a key enzyme catalyzing the last step of the transsulfuration pathway, cleaving cysteine from cystathionine, is undetectable in fetal liver, with activity appearing only postnatally [9]. In premature neonates, the low activity is associated with higher cystathionine and lower [cys] in plasma [15]. Both plasma cysteine [15] and hepatic de novo cysteine synthesis [10] rise in proportion to gestational age. Even though low plasma [cys] have been found in preterm infants receiving cysteine-containing parenteral amino acid solutions [46,47], cysteine deficiency seems to be relative, since both enterally-[16] and parenterally-fed [10,17] premature infants are able to produce cysteine. Demand may, however, exceed synthesis in case of RDS, as lower erythrocyte [cys] were observed in preterm infants on day 0, and in those who developed BPD or who died, both erythrocyte [cys] and [GSH] were found impaired on day 1 [39].

In the current study both GSH and cysteine were depleted in preterm infants at the time of birth, compared with term infants. The two substrates indeed are tightly linked. First, depletion of GSH decreases the synthesis of S-adenosylmethionine (SAM) by inhibition of L-methionine-S-adenosyltransferase [48,49]. As SAM is an allosteric activator of cystathionine β synthase, transulfuration is impaired and homocysteine is preferentially diverted to the transmethylation pathway [50], resulting in a lower cysteine availability for GSH synthesis. Accordingly, in a model of preterm baboon, supplementation with GSH, but not cysteine, prevented the decline in cysteine occurring postnatally [51]. Secondly, GSH is considered a cysteine reservoir, and low cysteine availability may increase GSH breakdown.

Besides cysteine, glutamate and glycine, the other two precursors of GSH, may affect fetal GSH availability. Glycine indeed is considered a conditionally essential amino acid in the neonate [52], and arises from the placental conversion of serine by serine hydroxymethyltransferase, which has a low activity in human placenta [53,54], whereas glutamate, is known to arise from the conversion of glutamine in fetal liver [55]. As the assay used in this study was developed to specifically assess GSH and cysteine, we cannot ascertain whether glutamate and/or glycine deficiency contributed to GSH depletion in VLBW cord blood.

The FSR measured ex vivo in the current study are approximately 5 times higher than those measured in vivo, e.g., 234% per day in umbilical arterial blood in preterm infants in this study, compared with approximately 45% per day in studies by Te Braake et al [56]. Several factors obviously contribute to the

---

**Table 2. Glutathione FSR (FSRGSH) and ASR (ASRGSH) in umbilical cord venous and arterial blood erythrocytes of preterm and full-term infants and in erythrocytes from their respective mothers.**

|           | Preterm birth | Full-term birth |
|-----------|--------------|----------------|
| n         | 8            | 8              |
| **FSR, %/d** |              |                |
| Umbilical vein | 145 [79–174] | 98 [75–126]    | 0.11 |
| Umbilical artery | 234 [84–256] | 93 [72–115]    | 0.08 |
| Maternal vein  | 110 [81–238] | 77 [65–115]    | 0.16 |
| **ASR, µmol/L per day** |          |                |
| Vein       | 740 [515–906] | 663 [560–969]  | 0.79 |
| Artery     | 651 [391–1222] | 551 [442–634]  | 0.46 |

Data are reported as median [interquartile]. No differences were observed between the samples collected at different gestational ages (p > 0.05) as assessed with the Mann-Whitney U test.

doi:10.1371/journal.pone.0002762.t002
difference between rates measured in vivo and ex vivo: (a) the freshly collected erythrocytes are lyzed, so equilibration of substrates between extra- and intracellular milieus become immaterial; and (b) erythrocytes are incubated with very high concentrations of all glutamate, cysteine and glycine, that largely exceed concentrations occurring in vivo. The in vivo method therefore measures the maximal capacity for GSH synthesis, when the erythrocyte enzymatic machinery is experiencing unlimited supply of precursor amino acids.

In the current study, the FSR\textsubscript{GSH}, measured ex vivo in neonatal erythrocytes, was indistinguishable between preterm and term infants, and close to maternal values (Table 2). This suggests that the observed GSH depletion may be due to increased utilization and/or insufficient substrate availability rather than to immaturity of synthetic capacity. This is in agreement with the early maturation of the enzymatic activity for GSH synthesis documented in earlier studies [9,57]. GSH is synthesized from glutamate, cysteine, and glycine in two consecutive steps by the action of $\gamma$-glutamylcysteine synthetase (GCS), which is rate-limiting, and GSH synthetase. GCS activity levels have been found in the same range in human foetal erythrocytes [58], leukocytes [57], liver [59], lung and kidney as are found in adults [60]. Short term regulation of GSH production by GCS occurs mainly via the availability of cysteine. The K\textsubscript{n} of rat liver GCS for cysteine is 100 \muM/L, near the upper end of typical cellular [cys], and the rate of GSH synthesis is extremely sensitive to changes in cellular cysteine level. GSH synthesis increases when intracellular cysteine levels increase as a result of increased saturation of GCS with cysteine, and this contributes to removal of excess cysteine. When cysteine levels drop, GCS activity increases and the increased capacity for GSH synthesis facilitates conservation of cysteine in the form of GSH, although the absolute rate of GSH synthesis still decreases because of the lack of substrate. Our results showing fully efficient FSR\textsubscript{GSH} in prematures are in agreement with this mechanism.

The unaltered FSR\textsubscript{GSH} observed for the VLBW infants in the current study concurs with a recent study that found no difference in FSR\textsubscript{GSH} on day 2 in prematures (<1500 g) receiving or not from birth an amino acid supplement in their parenteral nutrition [56]. Early amino acid infusion indeed increased blood [GSH] in VLBW infants, without any change in GSH FSR, suggesting amino acids may decrease GSH utilization, rather than increase GSH synthesis [56,61]. Taken together, the findings from the latter study and those from the current study point in the same direction: that substrate availability may be the limiting factor of maintaining adequate [GSH] after birth. Further studies using maternal infusion of labeled cysteine may thus be warranted to quantitate the rates of maternal-fetal cysteine transfer, and establish whether such transfer is lower in VLBW than term infants. If so, the supply of additional cysteine would become seem a reasonable option. However, intervention studies with cysteine supplied postnatally, even in high doses, failed to demonstrate an impact on FSR\textsubscript{GSH}, nitrogen balance, or weight gain. This may be, to some extent at least, because the included infants were not critically ill, or because [GSH] was already adequate [18,62]. As we show that deficiency is already present at the time of birth, and as [cys] drops dramatically after birth in premature infants due to either decreased cysteine synthesis, increased utilization, or excretion, the inefficacy of post-natal cysteine delivery may be due to a ‘late’ timing and it would be worthwhile to explore the putative benefit of cysteine supply prenatally, as we find [cys] to be consistently depleted in mothers of preterm infants.

Acknowledgments

We are grateful to the mothers who participated in these studies, and to the midwives at the Hôpital Mère-et-Enfant, CHU de Nantes, for their skillful help in patient care.

Author Contributions

Conceived and designed the experiments: AK DD IT. Performed the experiments: AK IT NW SLB CP. Analyzed the data: AK IT VFR DD JCR RJR. Wrote the paper: AK IT JCR NW RJR DD.

References

1. Smith CV, Hansen TN, Martin NE, McMicken HW, Elliott SJ (1993) Oxidant stress responses in premature infants during exposure to hyperoxia. Pediatr Res 34: 360–363.
2. Saugstad OD (1998) Free radical disease in neonatology. In: Saugstad OD, editor. Neonatal Intensive Care 3: 129–138.
3. Ahola T, Fellman, V, Kjellmer I, Raivio KO, Lapatto R (2004) Plasma $\gamma$-iso isoprostane is increased in preterm infants who develop bronchopulmonary dysplasia or periventricular leukomalacia. Pediatr Res 56: 80–85.
4. Thibeault DW (2000) The precarious antioxidant defenses of the preterm infant. American Journal of Perinatology 17: 167–181.
5. Jain A, Mehta T, Auld PA, Rodrigues J, Ward RF, et al. (1995) Glutathione metabolism in newborns: evidence for glutathione deficiency in plasma, bronchoalveolar lavage fluid, and lymphocytes in preterm infants. Pediatr Pulmonol 20: 160–166.
6. Nemeth I, Boda D (1994) Blood glutathione redox ratio as a parameter of oxidative stress in premature infants with IRDS. Free Radic Biol Med 1994; 16: 347–353.
7. Babaloo A, Reid M, Forrester T, Heird WC, Jahoor F (2002) Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr 76: 646–652.
8. Jahoor F, Jackson A, Gazzard B, Philips G, Sharpstone D, et al. (1999) Determination of glutathione and cysteine concentrations and $^2$H enrichments in microvolumes of neonatal blood using gas chromatography-mass spectrometry. Anal Bioanal Chem 390: 1403–1412.
9. Levonen AL, Lapatto R, Saksela M, Raivio KO (2000) Human cystathionase $\gamma$-lyase: development and in vitro expression of two isoforms. Biochem J 347: 291–295.
10. Shew SB, Keshen TH, Jahoor F, Jakobsen I, (2005) Assessment of cystine synthesis in very-low birth weight neonates using a $^{13}$C$_2$glucose tracer. J Pediatr Surg 40: 52–56.
11. Srurman JA, Gaull G, Raiha NC (1970) Absence of cystathionase in human fetal liver: is cysteine essential? Science 169: 76–78.
12. Gaull G, Sturman JA, Raiha NC (1972) Development of mammalian sulfur metabolism: absence of cystathionase in human fetal tissues. Pediatr Res 6: 536–547.
13. Hemmonen K, Raiha NC (1974) Induction of cystathionase in human fetal liver. Biochem J 144: 607–609.
14. Zlotkin SH, Anderson GH (1982) The development of cystathionase activity during the first year of life. Pediatr Res 16: 63–68.
15. Vina J, Veito M, Garcia-Sala F, Puertas IR, Gasco E, et al. (1995) L-cysteine and glutathione metabolism are impaired in premature infants due to cystathionase deficiency. Am J Clin Nutr 61: 1067–1069.
16. Riedijk MA, van Bekk RJ, Voortman G, de Bie HM, Dassel AC, et al. (2007) Cysteine: a conditionally essential amino acid in low-birth-weight preterm infants. Am J Clin Nutr 86: 1120–1125.
17. Thomas B, Grusca LL, Bennett C, Parmis P, Hansom RW, et al. (2008) Metabolism of methionine in the newborn infant: response to the parenteral and enteral administration of nutrients. Pediatr Res 64: 381–386.
18. Te Braake FWJ, Schierbeek H, Vermes A, Huijnums JGM, Van Goudoever JB (2009) High-dose cystine administration does not increase synthesis of the antioxidant glutathione preterm infants. Pediatrics 124: 978–984.
19. Kueter A, Tea I, Sweeney S, Roz JC, Robins RJ, et al. (2008) Simultaneous determination of glutathione and cysteine concentrations and $^4$H enrichments in microvolumes of neonatal blood using gas chromatography-mass spectrometry. Anal Bioanal Chem 390: 1403–1412.
20. Humbert B, Nguyen P, Ohled C, Robin C, Vasin A, et al. (2001) Use of $^{15}$N-glutamic acid and homoglutathione to determine both glutathione synthesis and concentration by GC/MS. J Mass Spectrom 36: 726–735.
21. Tea I, Ferchaud-Rouchez V, Kueter A, Darrain D, Robins RJ (2007) Determination of $^{13}$C isotopic enrichment of glutathione and glycine by gas chromatography/combustion/isotope ratio mass spectrometry after formation of the N- or N,3-ethoxy carbonyl methyl ester derivatives. Rapid Commun Mass Spec 21: 3245–3252.
22. Gitto E, Reiter RJ, Karbowiak M, Tan DX, Gitto P, et al. (2002) Causes of oxidative stress in the pre-and perinatal period. Biol Neonate 81: 146–157.
23. Viskova H, Vesela K, Janasikova B, Krijt J, Visek JA, et al. (2007) Plasma cysteine concentrations in uncomplicated pregnancies. Fetal Diagn Ther 22: 310–314.
24. Rajmakers MT, Roes EM, Steegers EA, van der Wildt B, Peters WH (2001) Umbilical cord and the plasma thiol concentrations in normal pregnancy. Clin Chem 47: 749–751.
25. Rajmakers MT, Roes EM, Poston L, Steegers EA, Peters WH (2006) The transient increase of oxidative stress during normal pregnancy is higher and persists after delivery in women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 130: 39–44.
26. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, et al. (2007) Free radicals and antioxidant enzymes in normal tissues and human disease. Int J Biochem Cell Biol 39: 44–84.
27. Wood JR Jr. (2001) Reactive oxygen species and preterm premature rupture of membranes review. Placenta 22 Suppl A pp S30–S44.
28. Rajmakers MT, Zusterzeel PL, Roes EM, Steegers EA, Mulder TP, et al. (2001) Oxidized and free whole blood thiols in preclampsia. Obstet Gynecol 97: 272–276.
29. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA (2000) Placental apoposis in preclampsia. Obstet Gynecol 96: 271–276.
30. Redman GW, Sargent IL (2001) The pathogenesis of pre-eclampsia. Gynecol Obstet Fertil 29: 518–522.
31. Vento M, Aguas M, Escobar J, Arshimi A, Ercrig R, et al. (2009) Antenatal steroids and antioxidant enzyme activity in preterm infants: influence of gender and timing. Antioxid Redox Signal 11: 2945–2955.
32. Giustarini D, Milzani A, Dalle-Donne I, Rossi R (2008) Red blood cells as a physiological source of glutathione for extracellular fluids. Blood Cells Mol Dis 40: 174–179.
33. Frosali S, Di Simplicio P, Perrone S, Di Giuseppe D, Longini M, et al. (2004) Glutathione recycling and antioxidant enzyme activities in erythrocytes of term and preterm newborns at birth. Biol Neonate 85: 138–149.
34. Jean-Baptiste D, Rudolph N (2003) Sequential postnatal changes in erythrocyte glutathione and sulfhydryl content: a possible adaptational response to the extrauterine environment. Biol Neonate 84: 142–146.
35. Lestas AN, Rodeck CH (1984) Normal glutathione content and some related enzymes in cord blood. Clin Chim Acta 142: 265–280.
36. Aloha T, Levenen AL, Fellman V, Lapatto R (2004) Thiol metabolism in preterm infants during the first week of life. Scand J Clin Lab Invest 64: 649–658.
37. Hiesmayr M, Schindler K, Pernicka E, Schuh C, Schoeniger-Hekele A, et al. (2006) Decreased food intake is a risk factor for mortality in hospitalised patients: the Nutrition Day survey 2006. Clin Nutr 25: 484–491.
38. Young VR, Bier DM, Pellett PL (1989) A theoretical basis for increasing current estimates of the amino acid requirements in adult man, with experimental support. Am J Clin Nutr 50: 80–89.
39. Rollins D, Larsson A, Steen B, Krishnaswamy K, Hagenfeldt L, et al. (1981) Glutathione and γ-glutamyl cycle enzymes in human fetal liver. J Pharmacol Exp Ther 217: 697–700.
40. Jackson AA, Gibson NR, Lu Y, Jaloor F (2004) Synthesis of erythrocyte glutathione in healthy adults consuming the safe amount of dietary protein. Am J Clin Nutr 80: 101–107.
41. Lecouvey I, Ronisso M, Marozzi AM, Perugini G, Corbetta C, et al. (1996) Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. Am J Obstet Gynecol 174: 1575–1583.
42. Roller MA, Lanza A, Colonetti S (2000) Transport of amino acids through the placenta and their role. Amino Acids 14: 517–523.
43. Van Goudoever JB, van den Akker CH, Wattimena DJ, Huijmans JG, van Goudoever JB (2005) Amino acid administration to premature infants directly after birth. J Pediatr 147: 457–461.
44. Cetin I, Ronisso M, Marozzi AM, Perugini G, Corbetta C, et al. (1996) Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. Am J Obstet Gynecol 174: 1575–1583.